Sedana Medical is a Swedish medical technology company that was founded in 2005 after acquiring the AnaConDa from Teleflex. The AnaConDa technology was originally developed by Louis Gibeck AB, a leader in heat and moisture exchangers. Our headquarters are based in Danderyd outside Stockholm in Sweden and in Ireland, where the company has its headquarters for R&D. The company’s business includes the development, marketing and sale of medical devices and drug development for future projects around AnaConDa. The AnaConDa enables simple delivery of volatile anaesthetics to invasively ventilated patients. The company’s product range includes AnaConDa and AnaConDa-S with relevant accessories.




Events not available


ICU Management

Sedana Medical Receives Approval for European Dossier

2021 20 Jul

Sedana Medical AB (publ) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation of mechanically ventilated adult patients during intensive care and should only be administered via the medical device AnaConDa.... Read more

ICU Management

Sedana Medical Announces Positive FDA Interaction

2021 07 Jul

Sedana Medical AB (publ) today announced that the company has completed a successful End of phase II meeting with the US Food and Drug Administration (FDA). The FDA accepted Sedana Medical's proposals for phase III program, including study design and primary endpoints for the studies. This positive outcome means that the company can enter phase III... Read more

ICU Management

Sedana Medical Receives QMS MDR Approval

2021 02 Jul

Sedana Medical AB (publ) today announced that the company has received an approval for its quality system (QMS) according to the EU Medical Device Regulation (MDR) 2017/745. The approval means that Sedana Medical's Class I medical device accessories can continue to be sold with CE marking within the EU. "The new EU Medical Device Regulation (MDR)... Read more

ICU Management

Sedana Medical's Sedaconda Study Awarded at DGIIN & ÖGIAIN

2021 22 Jun

Sedana Medical AB (publ) today announced that the company's pivotal phase III study Sedaconda (SED001) has been named one of the three best posters at the 52nd intensive care conference DGIIN & ÖGIAIN 16–18 June 2021. "It is very positive that the Sedaconda study is receiving this attention in Germany, which is our largest market. The strong study... Read more

Jobs not available


    Catalogue not available

Vendevägen 89,
SE-182 32
+46 (0)8 124 05 200

White Papers - Case Studies

Not available


    Videos not available


Not available


Not available

General inquiries
Email: [email protected]

Medical inquiries
Email: [email protected]

Investor relations
Email: [email protected]

For product feedback and complaints, please contact:[email protected]

Find Sedana Medical on Social Media